Biohaven (BHVN) Stock Price, Quote, News & History | Benzinga

SPY777.29−0.16%QQQ743.86−0.99%BTC/USD81,360.71−0.46%DIA518.08+0.38%GLD382.24−0.61%TLT77.97−0.01%

Biohaven Ltd (BHVN) Stock Price, Quote, News & History

BHVNNYSE

Trade with Public

Trade with Public

$11.79

-0.29-2.36%

Last update: Oct 12, 4:25 PM

$11.90

-0.18-1.49%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$11.91

Close

$11.80

Volume / Avg.

1.62M / 2.59M

Day Range

$11.90 - $11.90

52 Wk Range

7.48 - 18.57

Market Cap

$1.82B

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

38

Short Interest

16.14%

Days to Cover

6.43

Recent Biohaven Ltd. News

Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.

Vandana Singh

Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall

Avi Kapoor

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.

Avi Kapoor

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.

Vandana Singh

Why Is Biohaven Stock Soaring Wednesday?

Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-511.40M

Investing Cash Flow (TTM)

211.26M

Financing Cash Flow (TTM)

371.73M

Free Cash Flow (TTM)

-511.87M

Capital Expenditure (TTM)

-475.00K

Net Change in Cash (TTM)

71.60M

Analyst Trends and Forecast

2

1

May

1

Jun

2

Aug

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.4

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.85B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

149.29

Earnings Yield % (TTM)

-37.67%

Earnings Yield % (FWD)

-21.69%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.08

Company Debt

Total Debt

$259.48M

LT Debt

$259.48M

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-

Total Cash

$238.03M

Debt to Equity

24.30

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

-